SSA
TLSI icon

Schonfeld Strategic Advisors’s TriSalus Life Sciences TLSI Stock Holding History

Schonfeld Strategic Advisors’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-69,940
Closed -$695K – 3007
2022
Q3 		$695K Hold
69,940
– – 0.01% 1518
2022
Q2 		$689K Buy
69,940
+33,806
+94% +$332K 0.01% 1197
2022
Q1 		$354K Buy
36,134
+1,865
+5% +$18.4K ﹤0.01% 1580
2021
Q4 		$339K Sell
34,269
-20,731
-38% -$206K ﹤0.01% 1463
2021
Q3 		$546K Buy
55,000
+22,972
+72% +$225K 0.01% 1219
2021
Q2 		$311K Buy
32,028
+14,005
+78% +$137K ﹤0.01% 1453
2021
Q1 		$174K Buy
+18,023
New +$183K ﹤0.01% 1555

Other funds holding TLSI

MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
DFCM
Dark Forest Capital Management San Juan, Puerto Rico $1.13B AUM 18.74% 1-Year Est. Return
SIA
SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Schonfeld Strategic Advisors's TLSI Position: Q4 2022 in Review

Schonfeld Strategic Advisors sold out of TriSalus Life Sciences (TLSI) in Q4 2022, closing a stake of 69,940 shares — an estimated $695K sold.

Schonfeld Strategic Advisors first reported a position in TLSI in Q1 2021 and held it in 7 quarters. The position peaked at $695K in Q3 2022. 9 funds tracked by Wall St. Rank hold TLSI as of Q4 2022.

  • Schonfeld Strategic Advisors reported no remaining TriSalus Life Sciences position as of Q4 2022 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 69,940 TriSalus Life Sciences shares in Q4 2022, an estimated $695K.
  • Schonfeld Strategic Advisors first reported a position in TriSalus Life Sciences in Q1 2021 and held it in 7 quarters.
  • Schonfeld Strategic Advisors's TriSalus Life Sciences position peaked at $695K in Q3 2022.
  • 9 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q4 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.